Bankrupt Clovis faces delisting from Nasdaq
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS), which filed for Chapter 11 bankruptcy protection Dec. 11, has received a delisting notice from Nasdaq because of the filing.
Clovis reported the delisting in a filing Tuesday with the U.S. Securities and Exchange Commission.
“In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns related to the Bankruptcy Petitions,” according to Clovis’ SEC filing.
Clovis said that it would not appeal Nasdaq’s decision.
Trading of Clovis’ stock on Nasdaq will be suspended at the opening of…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
